Johnson & Johnson stock gains as dividend yield and oncology pipeline support valuation

Published on 09/17/2026 at 14:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock trades near the upper half of its 52-week range as of mid-September 2026, supported by a forward dividend yield around 1.97 percent. Recent oncology and neurology data add to the long-term case while consensus targets stay slightly above the current price.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) is trading near the upper half of its 52-week range, with shares opening at about USD 267.35 on the New York Stock Exchange on September 17, 2026, keeping the healthcare giant’s valuation in focus for income-oriented investors and long-term holders.

Stock holds near recent highs

According to MarketBeat on September 17, 2026, shares of Johnson & Johnson (NYSE: JNJ) opened at USD 267.35, reflecting a level close to recent highs and aligned with a 50-day moving average around USD 263.25 and a 200-day moving average near USD 246.40.

Earlier data compiled by ad-hoc-news.de indicate that Johnson & Johnson shares have traded between a 52-week low of USD 173.33 and a 52-week high of USD 281.07, placing the latest opening price of USD 267.35 significantly closer to the upper part of that range and roughly USD 13.72 below the high.

Valuation supported by income and pipeline

As Yahoo Finance reported on September 16, 2026, Johnson & Johnson’s most recent dividend amounted to USD 1.34 per share, implying an annualized forward payout of USD 5.36.

On a stock price around USD 267.80 cited in the same analysis, that payout translates into a forward dividend yield of approximately 1.97 percent, a level that is lower than some high-yield alternatives but is underpinned by the company’s diversified healthcare portfolio and long history of dividend growth.

In addition to the income component, Johnson & Johnson continues to invest heavily in its pharmaceutical pipeline. According to Yahoo Finance on September 16, 2026, new late-stage data associated with Caplyta showed improved sexual functioning among depression patients, broadening the commercial argument for this therapy area and contributing to sentiment on Johnson & Johnson’s broader neurology and psychiatry franchise.

Analyst targets and performance context

Based on data from MarketBeat as of September 17, 2026, Johnson & Johnson stock currently carries a consensus rating of Moderate Buy and an average analyst price target around USD 274.13, implying upside of roughly 2.5 percent from the opening level of USD 267.35 on the same day.

Looking at the performance backdrop, Trefis highlighted on September 16, 2026 that Johnson & Johnson shares had gained about 53 percent over the prior year, markedly outperforming the approximately 17 percent rise in the S&P 500 over the same period and leaving the healthcare name ahead of broad-market and sector benchmarks.

For investors, this combination of a modest forward yield, solid relative performance and a pipeline that includes oncology and neurology assets explains why the valuation premium has persisted even as the stock trades only a few percent below its 52-week high.

Next events and investor takeaway

Dividend timing remains an important consideration for shareholders relying on Johnson & Johnson stock for income. According to the dividend overview at Stock Analysis as of mid-September 2026, the company maintains a regular payout schedule, with ex-dividend and pay dates that have historically supported dependable cash flows for long-term holders; the most recent ex-dividend date precedes the September 2026 trading window and underpins the forward annualized payout referenced in recent coverage.

With Johnson & Johnson stock opening at USD 267.35 on the New York Stock Exchange on September 17, 2026, within roughly 5 percent of the 52-week high of USD 281.07 and backed by a market capitalization around USD 643.29 billion cited for mid-September 2026, the shares remain positioned as a large-cap defensive holding where incremental upside will likely depend on the next set of quarterly figures and further data from key late-stage programs.